AddThis

Depomed launches shingles drug

Gralise marketed for postherpetic neuralgia

MENLO PARK, Calif. — Depomed has launched a new drug for treating shingles, the drug maker said Monday.

The company announced the launch of Gralise (gabapentin) tablets, a once-daily treatment for postherpetic neuralgia, the pain that follows healing of the rash associated with shingles.

Gralise is a proprietary formulation of gabapentin that uses patented polymer technology that enables gradual release of the drug. Depomed said it is not interchangeable with other branded or generic gabapentin-based drugs.

 


Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

© 2014 Drug Store News. All Rights Reserved.